
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

For the Month of August 2022

001-36203
(Commission File Number)

CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its charter)

10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _____

This Report on Form 6-K is hereby incorporated by reference into the registrant's Registration Statements on Form S-8 (File No. [333-227753](#)) and Form F-3 (File Nos. [333-195124](#), [333-236064](#), [333-249063](#), and [333-262055](#)), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On August 29, 2022, Can-Fite BioPharma Ltd. (the "Company") announced that it postponed its annual general meeting of shareholders (the "Annual General Meeting"), which was scheduled for the same day. Accordingly, the Company's Annual General Meeting will be reconvened on Monday, September 5, 2022 at 3:00 p.m., Israel time at the Company's offices located at 10 Bareket Street, Petach Tikva, Israel.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 29, 2022

By: /s/ Pnina Fishman
Pnina Fishman
Chief Executive Officer

2
